---
title: "KPRX.US (KPRX.US) — 相關新聞"
type: "Symbol"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/quote/KPRX.US/news.md"
symbol: "KPRX.US"
name: "KPRX.US"
parent: "https://longbridge.com/zh-HK/quote/KPRX.US.md"
datetime: "2026-03-14T08:20:23.719Z"
locales:
  - [en](https://longbridge.com/en/quote/KPRX.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/KPRX.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/KPRX.US/news.md)
---

> 支持的語言: [English](https://longbridge.com/en/quote/KPRX.US/news.md) | [简体中文](https://longbridge.com/zh-CN/quote/KPRX.US/news.md)


# KPRX.US (KPRX.US) — 相關新聞

### [Kiora Pharmaceuticals to Present at Oppenheimer's 36th Annual Healthcare Life Sciences Conference](https://longbridge.com/zh-HK/news/276338683.md)
*2026-02-19T13:30:27.000Z*
> Kiora Pharmaceuticals, Inc. will present at Oppenheimer's 36th Annual Healthcare Life Sciences Conference on February 26

### [Korsana Biosciences Emerges From Stealth With $175 Millon In Funding](https://longbridge.com/zh-HK/news/276219691.md)
*2026-02-18T11:11:19.000Z*
### [Kiora Pharmaceuticals: Strong Financial Position and Promising Clinical Developments Drive Buy Rating](https://longbridge.com/zh-HK/news/265448589.md)
*2025-11-12T06:15:54.000Z*
> Analyst Michael Okunewitch of Maxim Group has maintained a Buy rating on Kiora Pharmaceuticals with a price target of $1

### [Earnings slated for Nov 7, 2025, with various companies like KPRX, DCBO, GYRE, RPID, GTN, ACRE, CTEV, AIRS, FLR & more expected to report.](https://longbridge.com/zh-HK/news/264851066.md)
*2025-11-07T11:12:32.000Z*
> Earnings reports are scheduled for November 7, 2025, from various companies including Kiora Pharmaceuticals, Docebo, Gyr

### [Kiora Pharmaceuticals Reports Third Quarter 2025 Results; Company Advances Pipeline with Two Actively Enrolling Phase 2 Clinical Trials for Retinal Diseases | KPRX Stock News](https://longbridge.com/zh-HK/news/264842313.md)
*2025-11-07T11:00:00.000Z*
> Kiora Pharmaceuticals reported its third quarter 2025 results, highlighting ongoing Phase 2 clinical trials for retinal 

### [Kiora Pharmaceuticals | 8-K: FY2025 Q3 Revenue: USD 0](https://longbridge.com/zh-HK/news/264844397.md)
*2025-11-07T11:10:56.000Z*
### [Kiora Pharmaceuticals | 10-Q: FY2025 Q3 Revenue: USD 0](https://longbridge.com/zh-HK/news/264844110.md)
*2025-11-07T11:09:18.000Z*